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Sir,
We read with interest the publication of Banks et al (1998) on the
significance of platelets for vascular endothelial growth factor
(VEGF) measurements. We disagree, however, with the conclu-
sion that for accurate measurement of circulating VEGF, serum is
completely unsuitable. We are also convinced that platelets are not
the sole origin of circulating VEGF. We would like to stress the
potential clinical usefulness of the determination of serum VEGF
levels in cancer patients based on published data and on some
recent original observations. In the studies described below, the
enzyme-linked immunosorbent assay (ELISA) methodology used
by Banks et al (1998) was applied.
In 44 untreated patients with disseminated colorectal cancer,
elevated serum VEGF, i.e. above 500 pg ml–1, was significantly
associated with fast tumour growth, i.e. estimated volume
doubling time of less than 6 months (Dirix et al, 1996), indepen-
dent of the number or site of metastasis, suggesting a predictive
value of serum VEGF for the progression of the disease. In 42
treated metastatic cancer patients, including patients with
colorectal, breast, ovarian and renal carcinomas, a significantly
higher fraction, i.e. 32%, of patients with progressive disease
during chemotherapeutic treatment had elevated serum VEGF
compared with 15% of patients showing response to treatment
(Dirix et al, 1997). In 82 patients with non-Hodgkin’s lymphoma,
followed up for at least 5 years, 71% of patients with lower than
the median serum VEGF before treatment had a 5-year survival
rate compared with only 49% among patients with a higher than
the median serum VEGF (P = 0.01) (Salven et al, 1997a). In
small-cell-lung cancer (n = 68), a high pretreatment serum VEGF
predicts poor response to chemotherapy (P = 0.008) and shorter
survival (P = 0.01) (Salven et al, 1998). The results of these and
other clinical studies (Salven et al, 1997b; Vermeulen et al, 1997)
suggest the potential relevance of measuring serum VEGF concen-
trations in cancer patients.
Because of the association of serum VEGF concentration and
platelet count in 27 breast cancer patients reported by Verheul et al
(1997) and the increase in VEGF concentration after activation of
platelet-rich plasma reported by Banks et al (1998), we have
compared the platelet count with serum VEGF and basic fibroblast
growth factor (bFGF) levels in 58 patients (142 measurements).
We found an association between platelet count and serum VEGF
(r = 0.50; 95% confidence interval 0.37–0.61; P < 0.0001) (Figure
1), but not between platelet count and serum bFGF (r = 0.06; P =
0.5). In 12 patients for whom we had four or more blood samples
at different times during treatment or follow-up, we analysed the
intrapatient association of serum VEGF and platelet count. In 10
out of 12 patients (83%), the blood sample with the highest platelet
count also had the highest serum VEGF level, although this was
the case for only 5 out of 12 patients (42%) for serum bFGF.
Changes in serum VEGF, i.e. increase or decrease, were congruent
with changes in platelet count in 82% of 39 changes. For serum
bFGF, this was the case for only 59% of all changes.
We argued that one of the reasons for the low coefficient of
correlation (r-value) of the association between serum VEGF and
platelet count might be the interindividual difference in the ratio
between serum VEGF and platelet count. Of all 142 blood
samples, the mean ratio of VEGF and platelet count was 1.39 pg
VEGF per 106 platelets (standard deviation 0.96; median 1.16;
range 0.16–4.96). The coefficient of variation was, therefore, 69%.
The individual coefficients of variation were much lower. Twenty-
three patients, with three or more measurements, were analysed.
Mean coefficient of variation was 26% (standard deviation 14;
median 23; range 6–56), indicating that interindividual variation
of the ratio between serum VEGF and the number of platelets is
larger than intraindividual variation. A positive association
between serum VEGF and the ratio between serum VEGF and
platelet count was also noted (r = 0.83; 95% confidence interval
0.78–0.88; P < 0.0001). If, as can be concluded from the more than
tenfold higher VEGF concentrations in serum compared with
plasma and the invariably low levels of plasma VEGF in Table 2
of the publication of Banks et al (1998), the majority of circulating
VEGF protein is associated with platelets, this means that the
amount of VEGF per platelet is different from patient to patient.
So, serum VEGF does not only reflect platelet count. Indeed,
VEGF mRNA can also be detected in other cell fractions of the
peripheral blood, including monocytes, granulocytes and lympho-
cytes (Wartiovaara et al, 1998).
The mitogenic activity on endothelial cells of the sera of 20
cancer patients was compared with that of fetal calf serum. The
patients’ sera with bFGF concentrations higher than the cut-off
value which correlates with fast growth kinetics (Dirix et al,
1996), i.e. 7.5 pg ml–1, stimulated human umbilical vein endothe-
lial cell (HUVEC) proliferation significantly more, i.e. 1.7 times
(1.3–2.3), than the control serum only when the VEGF concentra-
tion in the sera was also elevated, i.e. higher than 500 pg ml–1. In
sera with low-bFGF or low-VEGF content, no stimulation of
HUVEC proliferation was observed. Therefore, we conclude that
serum VEGF measurements in cancer patients correspond to the
degree of mitogenic activity of the serum on endothelial cells.
Given the association of serum VEGF with the clinical course of
cancer patients, the lack of a strong association between serum
VEGF and platelet count, and the association of serum VEGF with
the degree of stimulation of endothelial cell proliferation in vitro, we
conclude that measuring serum VEGF might be more suitable in
cancer patients than measuring plasma VEGF. Taking into account
errors caused by sample handling and the fact that VEGF mRNA is
also present in other blood cells, measuring VEGF in whole blood
might even be more accurate. Recent results (P Salven, unpublished
data) indeed suggest that using whole blood when measuring circu-
lating VEGF may improve the clinical significance.
It is tempting to speculate on the mechanism responsible for the
association between platelet count and serum VEGF. Although
megakaryocytes produce VEGF (Möhle et al, 1997), in cancer
patients another, and presumably important, source of circulating
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VEGF is the tumour. An interesting hypothesis is that in fast-
growing tumours, in addition to up-regulation of VEGF, the
production of a potent thrombopoietic cytokine, e.g. interleukin 6
(IL-6) (Ishibashi et al, 1989), would be increased. Indeed, like
VEGF, IL-6 is up-regulated by hypoxia (Yan et al, 1995) and IL-6
expression is elevated in tissues that undergo active angiogenesis,
such as healing wounds (Mateo et al, 1994). Moreover, response
elements for IL-6 signalling have been found upstream to the tran-
scription initiation site of VEGF, and treating cell lines with IL-6
resulted in induction of VEGF mRNA (Cohen et al, 1996). We
have observed twofold higher serum VEGF levels in malignant
mesothelioma patients compared with breast and colorectal cancer
patients (Kumar-Singh et al, 1997). Among patients with malig-
nant mesothelioma, a high incidence of thrombocytosis has been
reported, which is associated with high levels of circulating IL-6
(Nakano et al, 1998). Benign angiogenic diseases are also charac-
terized by thrombocytosis. For example, in inflammatory bowel
disease, elevated serum levels of angiogenic factors and of IL-6,
and high platelet count, are associated with exacerbation of disease
(Lake et al, 1978; Bross et al, 1996; Bousvaros et al, 1997).
From a physiological point of view, platelets could, thus, be
regarded as scavengers of circulating VEGF, in order to restrict the
angiogenic activity to sites of wound healing, of growing organs,
of inflammation and, in the case of cancer patients, of tumour
progression. This mechanism would explain part of the contradic-
tion between the high-angiogenic activity of cancer patients’
serum and the lack of angiogenesis outside the tumour tissue.
Activated platelets have indeed been found to release VEGF
together with b-thromboglobulin, suggesting that VEGF resides in
the  a-granules of the platelets (Wartiovaara et al, 1998). This
leaves open the possibility that at least part of the VEGF in
platelets has been endocytosed from the plasma.
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Figure 1 Association of serum VEGF and platelet count in 58 cancer
patients (142 samples) r = 0.5, P < 0.0001. Serum VEGF was analysed by
ELISA (Quantikine human VEGF, R & D Systems, Minneapolis, MN, USA)372 Letters to the Editor
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Sir,
The letter by Vermeulen et al raises interesting possibilities about
platelets and the measurement of circulating vascular endothelial
growth factor (VEGF), several of which we alluded to in our orig-
inal publication (Banks et al, 1998). It is now apparent that many
haematological cells are capable of producing or releasing VEGF,
including platelets, megakaryocytes, CD34+ cells, monocytes, T-
lymphocytes and neutrophils (Freeman et al, 1995; Katoh et al,
1995; Gaudry et al, 1997; Möhle et al, 1997; Verheul et al, 1997;
Banks et al, 1998). However, the extent to which these cells
normally contribute to the circulating VEGF pool in vivo and the
physiological or pathological relevance is not yet clear.
The measurement of VEGF in citrated plasma under the
descriptions described in our study (Banks et al, 1998) is most
likely to reflect the true circulating VEGF concentration, i.e. any
soluble VEGF which is not cell associated. The basic concept
behind the measurement of systemic concentrations of cytokines is
that it reflects localized events in particular organs because of an
‘overspill’ effect. In the case of VEGF, the hope is that the
increased production of VEGF within a tumour is reflected by an
increased circulating concentration, which may allow its use as a
marker of angiogenesis. Clearly, if there is a constitutive produc-
tion of any cytokine, this will form the basis for the baseline levels
of cytokine measured in the absence of any disease, and will
depend on the rate of production and entry into the circulation
and its subsequent removal. Therefore, production of VEGF by
tissues undergoing physiological angiogenesis, for example
endometrium, is most likely to determine the normal circulating
levels. Platelets are capable of producing VEGF endogenously
with the demonstration of mRNA within platelets and mega-
karyocytes and the secretion of VEGF by both platelets and
megakaryocytes after activation, but occurring constitutively only
in megakaryocytes (Katoh et al, 1995; Mohle et al, 1997).
Therefore, under normal circumstances, platelets may be expected
to contribute minimally to the circulating concentrations of VEGF.
The main exception to this would be, however, if platelets are
serving as a ‘scavenger’ of circulating VEGF, as proposed by
Vermeulen et al, and removing it from the circulation by endo-
cytosis (for which there is as yet no published evidence). Then a
dynamic equilibrium may exist in which their content varies
depending on the production of VEGF as a result of the underlying
disease process.
The measurement of serum concentrations of VEGF is an artifi-
cial situation and measures both the freely circulating VEGF and
that released by platelets upon activation during the clotting
process. Although other cell types, for example neutrophils, may
also contribute to the serum VEGF, the significant correlation
found in our study between platelet-derived VEGF in platelet-rich
plasma in which other cell types are absent and theoretical platelet-
derived VEGF in corresponding serum samples (r = 0.95,  P <
0.001) makes it extremely likely that platelets are the main cellular
source of serum VEGF (Banks et al, 1998). The fact that more
recent studies are now demonstrating significant relationships
between serum VEGF concentrations and clinical indices, as
discussed by Vermeulen et al, is clearly of considerable biological
interest. This may arise because of the proposed ‘scavenger’ func-
tion of platelets in endocytosing VEGF, but also equally may
partly reflect platelet number which changes in many disease
states including cancer. In support of this latter possibility,
cyclical changes in serum VEGF concentration were found
during chemotherapy, coinciding with the chemotherapy-induced
thrombocytopenia and subsequent rebound increase in platelet
number, rather than a sustained decrease in VEGF levels which
would be expected if the tumour-derived VEGF was to decrease as
a result of chemotherapy (Verheul et al, 1997). In agreement with
the much larger study described by Vermeulen et al, we found
marked interindividual variation in platelet VEGF content (Figure
2, Banks et al, 1998) and agree that differences in platelet content
of VEGF as well as platelet number can also markedly influence
serum VEGF concentration. Another point to bear in mind, partic-
ularly when examining correlations between platelet number and
serum VEGF, is that serum VEGF concentrations are determined
by the platelet-derived VEGF and circulating VEGF levels, and
that if the latter increases with disease state (as can be determined
from measurements using plasma) then this can become an
increasingly important component of the serum VEGF concentra-
tion. This may account for the relatively low correlation coeffi-
cients between platelet number and serum VEGF. It may be more
accurate to examine the correlation between platelet number and
VEGF concentration measured as the difference between serum
and plasma levels.
It is evident that further research is needed to investigate further
the role of platelets in both physiological and pathological situa-
tions involving VEGF, and into whether serum measurements are
providing clinically useful information only owing to the reflec-
tion of platelet numbers or for the other reasons discussed. We are
currently carrying out a preliminary study examining the relation-
ship between circulating plasma and serum VEGF concentrations,
platelet number and the tissue expression of VEGF in patients with
breast cancer which may provide some answers, but clearly other
major studies are needed.
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Sir,
In a recent paper, Hjalgrim et al (1998) reported a surprisingly
high incidence of Kaposi’s sarcoma (KS) in Iceland and the Faroe
Islands. No explanation for the high incidence rates of KS in these
two North Atlantic communities was identified.
Soil parent materials of Iceland and the Faroe Islands are mainly
extrusive igneous rocks, which are characterized by the presence
of mafic (iron oxide-rich) minerals (Krauskopf, 1979). These
minerals are known to be highly weatherable (Ollier, 1984),
allowing a significant release of iron compounds into the environ-
ment, such as in vegetables. Interestingly, a similar magmatic
substrate is present in the Mediterranean area (e.g. Sicily, Sardinia)
and in subtropical Africa; both areas are known to exhibit high
incidence rates of KS. In this connection, a previous study (Ziegler,
1993) found that African endemic KS shows a distribution that
conforms geographically to the iron oxide-rich volcanic clays of
the East African Rift System. We, therefore, suggest that some
environmental factors related to the presence of melanocratic rocks
(mafic minerals) might be involved in the high incidence rates of
KS in Iceland and the Faroe Islands.
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1Departments of Dermatology and 2Internal Medicine, Erasme
University Hospital, B-1070 Brussels, Belgium; 3Laboratory of
Plant Genetics and Ecology, Free University of Brussels, B-1160
Brussels; 4Department of Infectious Diseases, Algemeen
Ziekenhuis Sint Jan, 8000 Brugge, Belgium
REFERENCES
Hjalgrim H, Tulinius H, Hardarson S, Frisch M and Melbye M (1998) High
incidence of classical Kaposi’s sarcoma in Iceland and the Faroe Islands.
Br J Cancer 77: 1190–1193
Krauskopf KB (1979) Introduction to Geochemistry. McGraw-Hill, Kogakusha:
London
Ollier C (1984) Weathering. Longman Group: Essex
Ziegler JL (1993) Endemic Kaposi’s sarcoma in Africa and local volcanic soils.
Lancet 342: 1348–1351
Gaudry M, Brgerie O, Andrieu V, El Benna J, Pocidalo MA and Hakim J (1997)
Intracellular pool of vascular endothelial growth factor in human neutrophils.
Blood 90: 4153–4161
Möhle R, Green D, Moore MAS, Nachman RL and Rafii S (1997) Constitutive
production and thrombin-induced release of vascular endothelial growth factor
by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663–668
Verheul HMW, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC,
Broxterman HJ and Pinedo HM (1997) Platelet: transporter of vascular
endothelial growth factor. Clin Cancer Res 3: 2187–2190
Freeman MR, Schneck FX, Gagnon ML, Corles C, Soker S, Niknejad K, Peoples
GE and Klagsbrun M (1995) Peripheral blood T lymphocytes and lymphocytes
infiltrating human cancers express vascular endothelial growth factor: a
potential role for T cells in angiogenesis. Cancer Res 55: 4140–4145
Katoh O, Tauchi H, Kawaishi K, Kimura A and Satow Y (1995) Expression of the
vascular endothelial growth factor (VEGF) receptor gene, KDR, in
hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death
caused by ionizing radiation. Cancer Res 55: 5687–5692
High incidence of Kaposi￿s sarcoma in Iceland and the
Faroe Islands
Survival and determinants of response to third-line
chemotherapy in sensitive recurrent ovarian cancer
patients
Sir,
More than 70% of ovarian cancer patients achieve a partial or
complete response to first-line chemotherapy (McGuire et al,
1996; Bolis et al, 1997). Most of them, however, will recur (Neijet
et al, 1991; Bolis et al, 1996). The results of second-line treatment
depend largely on the platinum-free interval (Markman et al,
1991), patients who relapse 6 months after primary chemotherapy
having a higher response rate to platinum treatments (Thigpen
et al, 1993; Bolis et al, 1994a). Unfortunately, the response is
relatively short lasting, and most patients need a third-line
chemotherapy.
Data on response to third-line chemotherapy in ovarian cancer
patients responding to prior treatments are lacking. We analysed
the response to third-line chemotherapy in a series of women
responsive to first- and second-line therapy for ovarian cancer.
They were observed between 1984 and 1997 in a network of
centres collaborating in three randomized trials on second-line
therapy for recurrent advanced ovarian cancer ³ 6 months after
first-line chemotherapy (Zanaboni et al, 1991; Bolis et al, 1994a,
1994b). As of June 1997, 56 out of 223 cases included in these
trials had a second relapse after complete or partial response to
second-line chemotherapy, including platinum-based compounds
alone or in combination. Of these, 49 (median age 51 years, range
30–70) received third-line chemotherapy; these women are
considered in this report.
Histological types at first diagnosis were: serous in 36 cases
(74%), endometrioid in seven (14%) and others in six (12%).
Grading was: (1) in two patients (4%); (2) in 14 (29%); and (3) in
33 (67%). Response to second-line treatment was complete in 31
patients (63%) and partial in 18 (37%) with a median duration of
10 months (range 3–60). A total of 13 (27%) relapsed within
6 months from second-line treatment and 36 (73%) after 6 months
or more.374 Letters to the Editor
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Third-line chemotherapy regimens included topotecan or plat-
inum compounds alone or platinum compounds in combination
with anthracyclines or taxanes.
No women were lost to follow-up (median follow-up 11
months, range 2–53). Survival and response data were updated to
August 1997.
Forty-seven women were evaluated for response to third-line
chemotherapy, two patients did not complete planned treatments.
Complete and partial response was observed, respectively, in 12
(27%) and in ten (21%) cases (Table 1). Overall response rate was
49%, with a median duration of 6 months (range 1–23).
A significant difference in 1-year survival was observed
between responders (82%) and non-responders (39%, P < 0.05).
Median survival was 16 months (range 4–53) in the first group and
9 months (range 1–31) in the second.
There were no differences in response according to patients’
characteristics at first diagnosis. The response rate tended to be
higher in patients with a complete remission (52%) to second-line
treatment than those who had a partial one (37%), though the
difference was not significant (Table 1).
Time to progression from last treatment, site of second relapse
and type of third-line chemotherapy regimen seemed to have no
marked impact on response, but we observed a higher response
rate in patients who relapsed 6 months or more after salvage
therapy (50%) than those who recurred before 6 months (38%);
again, the difference was not significant.
Up to now, ovarian cancer patients were treated with third-line
chemotherapy in phase I and II studies to test new agents and
combinations (Eisenhauer et al, 1994; Kaye et al, 1995), but few
studies have evaluated the determinants of response, which may be
useful to identify patients who can benefit from third-line treat-
ment. Our study found that about half of relapsing patients respon-
sive to first- and second-line chemotherapy could benefit from
third-line chemotherapy, though the response was short lasting.
The frequency of response seems to be higher in patients who
obtained complete remission to prior treatments. In the next few
years, these findings may be useful with the introduction of novel
antineoplastic drugs that will permit new therapeutic options.
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Table 1 Response and 1 year survival to third-line chemotherapy according
to selected characteristics relapse
Response
Yes (%)a No (%)
Total 22 (49) 23 (51)
Characteristic at diagnosis
Age
≤55 14 (44) 18 (56)
>55 8 (53) 7 (47)
Grade
1 2 (100) – (0)
2 3 (25) 9 (75)
3 17 (52) 16 (48)
Histotype
Serous 15 (43) 20 (57)
Endometrioid 4 (67) 2 (33)
Others 3 (50) 3 (50)
Response to second-line chemotherapy
Complete 16 (52) 15 (48)
Partial 6 (37) 10 (63)
Time to progression after second-line
chemotherapy (months)
<6 5 (38) 8 (62)
³6 17 (50) 17 (50)
Site of second relapse
Pelvic/abdominal 18 (49) 19 (51)
Extra-abdominal 4 (40) 6 (60)
Third-line chemotherapy regimens
Monochemotherapy 12 (44) 15 (56)
Polychemotherapy 10 (50) 10 (50)
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Sir,
A recent report by Delic et al (1998) showed that lactacystin sensi-
tizes human leukaemia cells to the proapoptotic action of tumour
necrosis factor alpha (TNF-a). This effect was attributed to the
inhibition of the proteasome, assuming that lactacystin is a specific
inhibitor of the latter. However, in a recent report (Ostrowska et al,
1997), it was shown that lactacystin is also capable of inhibiting
the carboxypeptidase activity of cathepsin A. Therefore, any
conclusions regarding the mechanism of action of lactacystin, as
due to the inhibition of the proteasome alone, should be accepted
only with caution. In another report (Wójcik et al, 1997), we have
shown that a selective proteasome inhibitor of a different type
(peptidyl-aldehyde) – PSI – induces apoptosis of L1210 murine
leukaemia cells. Incubation of PSI-treated cells with 10 ng ml–1 or
100 ng ml–1 human TNF-a did not result in any increased rates of
cell death, whereas TNF-a alone induced a measurable effect. As
PSI also inhibits calpains, Z-leu-leucinal (ZLL), a calpain inhibitor
without effects on the proteasome, was used as a control.
A similar approach was used to another cell line, B16F10
murine melanoma. Our experiments revealed that B16F10
melanoma cells cultured in vitro are very sensitive to PSI, which
induces apoptotic changes and characteristic concentration of
protein conjugates (Figure 1) in nanomolar concentrations
although ZLL does not. PSI was dissolved in DMSO and no
apoptotic effect was observed in cell cultures incubated with
DMSO alone (the final solution in culture medium was less than
0.5%). The cytotoxic/cytostatic effect of PSI was dose dependent
(Figure 2). TNF-a alone moderately inhibited the proliferation of
melanoma cells. Only at the lowest PSI dose (5 nM) has there
been an additive apoptosis promoting effect of TNF-a with PSI.
At higher PSI doses, there was no difference if TNF-a was
added to the culture or not, regardless of the time at which it was
added to cell cultures (simultaneously or 1 or 2 days after PSI; data
not shown).
It seems that suppression of NF-kB activation may be crucial to
allow proapoptotic compounds to exert their effect (Wang et al,
1996), but as we have shown these result may be limited only to
certain conditions and certain cell types.
Inhibition of proteasome, apoptosis and sensitization to
tumour necrosis factor alpha: do they always go
together?
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Figure 1 B16F10 melanoma cells untreated (A) and treated with 5 mM PSI for 24 h (B), stained with amido black 10B. Arrows indicate perinuclear protein
conjugates accumulated upon proteasome inhibition. Two other treated cells already display chromatin condensation. Bar = 20 mm
Figure 2 Comparison of cytostatic/cytotoxic effects toward B16F10
melanoma cells in the absence or presence of increasing PSI or ZLL and
TNF-a concentrations after 72 h incubation. Relative viability, expressed as
per cent of control, was measured by the MTT assay, as described
previously (Lasek et al, 1996). Standard deviations are indicated by vertical
bars. The groups which differed significantly from control (P < 0.05, Student’s
t-test) are indicated by asterisks
PSI 0
PSI 5 ´ 10–9 M
PSI 5 ´ 10–8 M
PSI 5 ´ 10–7 M
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